IRD - NASDAQ

OG

Opus Genetics, Inc.

IRDยทNASDAQ

$4.38

+9.9%
HealthcareBiotechnology

Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$356.92M
EPS-0.8000
P/E Ratio-5.48
Earnings Date08/12/2026
OG

Opus Genetics, Inc. Fair Value Envelope

IRD ยท NASDAQ

Our analysis suggests that IRD has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.385, this represents a potential HIDDEN relative to our calculated worth for Opus Genetics, Inc..

HIDDEN
Intrinsic Value
Current Price: $4.385

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$47.6M
+ Cash & Equivalents$45.1M
Firm Value-$2.5M
- Debt$0
Equity Value-$2.5M
/ Shares Outstanding59,908,055B
DCF Value-$0
OVERVALUED BY 101%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$21.9M
-$13.6M
-$8.5M
-$5.3M
-$3.3M
-$2.0M
-$1.3M
-$786.1K
-$488.7K
-$303.8K
Maintenance CapEx
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
-$0
Owner Earnings
-$21.9M
-$13.6M
-$8.5M
-$5.3M
-$3.3M
-$2.0M
-$1.3M
-$786.1K
-$488.7K
-$303.8K
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$20.3M
-$11.7M
-$6.7M
-$3.9M
-$2.2M
-$1.3M
-$737.9K
-$424.7K
-$244.5K
-$140.7K
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your IRD research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.